Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 19 clinical trials
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY)

The current study aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy.

adjuvant therapy
invasive breast cancer
breast cancer
  • 09 Jul, 2022
  • 6 locations
Targeted Biopsy of Carbon Nanoparticles Labelled Axillary Node for cN+ Breast Cancer

To explore the feasibility of target biopsy of carbon nanoparticles labelled lymph node after neoadjuvant systemic therapy for cN+ breast cancer, and evaluate whether it can accurately predict axillary lymph node status after neoadjuvant systemic therapy.

  • 01 Jul, 2022
  • 1 location
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling (FB-12)

This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.

pet-ct scan
progesterone receptor
neutrophil count
  • 20 Jun, 2022
  • 43 locations
Enhanced Bioscaffold for Volumetric Muscle Loss (MTEC VML)

This is a prospective, single center study conducted at the University of Pittsburgh designed to test the applicability and utility of XenMatrix™ AB Surgical Graft in the restoration of function in the setting of volumetric muscle loss after soft tissue trauma.

  • 27 Feb, 2022
  • 1 location
Assess the Use of rEBUS With a Guide Sheath to Increase Transbronchial Lung Biopsy Yield Rate

Whether using a guide sheath can increase the diagnostic yield rate after the lesion is located by radial endobronchial ultrasound

endobronchial ultrasonography
  • 28 Oct, 2021
  • 1 location
Omission of Breast Surgery for Predicted Pathologic Complete Response Patients With MRI and Vacuum-assisted bIopsy in Breast Cancer After Neoadjuvant Chemotherapy a Multicenter, Single-arm, Non-inferiority Trial (OPTIMIST)

A prospective, multicenter, single-arm non-inferiority trial to demonstrate that breast cancer patients who are predicted to have a pathologic complete response on MRI and vacuum-assisted biopsy after neoadjuvant chemotherapy, and are omitted breast surgery have a non-inferior 5-year disease-free survival compared to those who had received breast surgery.

  • 28 Oct, 2022
  • 1 location
Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Metastatic Lung Cancer and Metastatic Melanoma Receiving Post-progression Immune Checkpoint Inhibitor Therapy

This research study is studying cryoablation (a treatment to kill cancer cells with extreme cold) combined with continued treatment with current immune checkpoint inhibitor as a possible treatment for lung cancer.

ct scan
lung carcinoma
spiral computed tomography
  • 04 Mar, 2022
  • 1 location
Axillary Lymph Node Tattoo Marking Study

> Core needle biopsy and/or fine needle aspiration Surgical Removal of the Lymph Nodes via clip and radioseed guidance

core needle biopsy
  • 24 Mar, 2022
  • 1 location
Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas

This phase I/II trial tests the safety, side effects, and best dose of entinostat and ZEN003694 in treating patients with solid tumors or lymphoma that has spread to other places in the body (advanced) or does not respond to treatment (refractory). Entinostat may stop the growth of cancer cells by …

measurable disease
tumor cells
cancer chemotherapy
neutrophil count
  • 15 Oct, 2022
  • 2 locations
Three Fraction Radiation to Induce Immuno-Oncologic Response

Patients with high risk breast cancers (any locally advanced breast cancer patient defined as Stages IIB-III [excluding inflammatory breast cancer] with stage IIA being eligible for triple negative and HER2-positive breast cancers) will receive neoadjuvant radiation to any portion of their tumour in three fractions in order to act as …

  • 18 Aug, 2021
  • 1 location